Correlation between mass of muscle and effect of lenvatinib in patients with hepatocellular carcinoma
Not Applicable
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000037380
- Lead Sponsor
- Kitasato University school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
i) child-pugh class C, ii) poorly controlled ascites, iii) severe renal dysfunction iv) malignancy except hepatocellular carcinoma
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The influences of SMI on the occurrence of drug withdral due to severe adverse events (AEs).
- Secondary Outcome Measures
Name Time Method We also investigated the influences of SMI on TTF (Time to treatment failure) and Overall survival(OS).